Pre-Open Movers 12/09: (THOR) (XBIT) (ARQL) Higher (DPLO) (THO) (M) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Rocket Pharmaceuticals (RCKT) Prices 3.82M Share Common Offering at $22.25/Sh
December 11, 2019 5:59 AM ESTRocket Pharmaceuticals, Inc. (NASDAQ:... More
Rocket Pharmaceuticals (RCKT) Announces Proposed Common Share Offering
December 10, 2019 4:02 PM ESTRocket... More
Agios Pharma (AGIO) Reports Updated Data for Mitapivat from Extension Phase of DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
December 9, 2019 10:13 AM ESTAgios Pharmaceuticals, Inc. (NASDAQ: AGIO) today reported new data from the extension phase of the DRIVE PK Phase 2 study of mitapivat (AG-348) in adults with pyruvate kinase (PK) deficiency at the 2019 American Society of Hematology (ASH) Annual Meeting. Mitapivat is an investigational, first-in-class, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes that directly targets the underlying metabolic defect in PK deficiency, a rare, potentially debilitating, hemolytic anemia. In addition, data was shared from the Agios-sponsored Natural History Study of PK deficiency that detailed the comorbidities and... More
